GSK starts Phase III study for severe asthma treatment

GSK has announced today that the first patient has been dosed in part of their Phase III clinical trial investigating the safety and efficacy of GSK3511294 (GSK’294) in severe eosinophilic asthma (SEA).

The investigational medicine, GSK’294, has the potential to be the first biologic to deliver long-acting suppression of IL-5 in patients with SEA from one subcutaneous injection every six months.

read more